Preformulation Studies of Methotrexate and Aceclofenac for Formulation and Development of Solid Lipid Nano-Particles: Novel Drug Delivery

The primary objective of preformulation testing is to generate information that formulators can utilize to design stable, bioavailable, secure and efficient dosage forms.Preformulation research considers the early optimization of drug delivery by identifying the physiochemical characteristics of the substance that may impact medication performance.By using capillary fusion, the melting point was found.The drugs MTX and ACE, selected for the present study, were identified using various literaturereported methods, including melting point determination, partition coefficient analysis, and absorption maxima (λmax) measurement FTIR spectroscopy and drug excipient interaction studies. The obtained data from these studies were matched with the data given in standard monographs.The melting point for MTXandACE was recorded at 180-191˚C and 147-153ºCrespectively. The partition coefficient value log P was found to be - 1.9 ± 0.25 and 1.86 ± 0.75 respectively. Data of solubility study indicates that Methotrexate was freely soluble in acetone and pH 6.8 Phosphate buffer, insoluble in water, chloroform and methanol and slightly soluble in 0.1 N HCl.Aceclofenacwas soluble in acetone, methanol & chloroform, sparingly soluble in methanol &alchohol.The FTIR peak of test sample Methotrexate &Aceclofenacwere matches with that of standard spectra especially in fingerprint region thereby confirming the identity of both drug.